<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187368</url>
  </required_header>
  <id_info>
    <org_study_id>020-1601-001-P01</org_study_id>
    <nct_id>NCT01187368</nct_id>
  </id_info>
  <brief_title>Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System</brief_title>
  <acronym>COMPETENCE</acronym>
  <official_title>Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System: the COMPETENCE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evaheart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evaheart, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, unblinded, randomized, controlled, and non-inferiority&#xD;
      study comparing the EVA2 LVAS to the most recent magnetically levitated centrifugal LVAS (HM3&#xD;
      LVAS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult (&gt;18 years old), advanced heart failure NYHA Class IV patients who are refractory to&#xD;
      advanced heart failure management and meet study Inclusion/Exclusion criteria will be&#xD;
      enrolled.&#xD;
&#xD;
      The objective of the study is to evaluate the safety and effectiveness of the EVA2 by&#xD;
      demonstrating non-inferiority to commercially approved LVADs when used for the treatment of&#xD;
      refractory NYHA Class IV heart failure.&#xD;
&#xD;
      Subjects will be followed for 6 months (short-term cohort) and 24 months (long-term cohort)&#xD;
      after EVA2/HM3 LVAS implantation or until outcome events of transplantation, explantation,&#xD;
      death or withdrawal, whichever occurs first. Whereas subjects experiencing the outcome events&#xD;
      of &quot;Severe RHF&quot; and &quot;Disabling stroke&quot; will remain in study follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-Term Primary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Survival to cardiac transplant or device explant for recovery free from disabling stroke (Modified Rankin Score &gt; 3) or pre-defined severe Right Heart Failure at 6 months after implantation of the originally implanted device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-Term Primary Endpoint</measure>
    <time_frame>24 months</time_frame>
    <description>Survival to cardiac transplant or device explant for recovery free from disabling stroke (Modified Rankin Score &gt; 3) or pre-defined severe Right Heart Failure at 24 months after implantation of the originally implanted device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in KCCQ and EuroQol</measure>
    <time_frame>Baseline versus POD 30, 90, 180, 360 and every 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk test</measure>
    <time_frame>Baseline versus POD 30, 90, 180, 360 and every 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>Baseline versus POD 30, 90, 180, 360, and every 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and incidence of all re-operations</measure>
    <time_frame>Discharge after implant through transplant or explant for recovery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and incidence of all rehospitalizations</measure>
    <time_frame>Discharge after implant through transplant or explant for recovery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, serious adverse events and UADEs</measure>
    <time_frame>Implant through transplant or explant for recovery (+60 days or discharge) or 180 days on device; then duration of device support, up to 360 days (approximate)</time_frame>
    <description>Peri-operative complications and any failure to successfully implant the device.&#xD;
All adverse events occurring during the acute and chronic phase of the study (frequency, severity, duration, sequelae and relationship to device).&#xD;
All adverse events occurring during the extension phase (frequency, severity, duration, sequelae and relationship to device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all device failures and device malfunctions</measure>
    <time_frame>Implant through transplant or explant for recovery (+60 days or discharge) or 180 days on device; then duration of device support, up to 360 days(approximate)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-transplant or post-explant survival</measure>
    <time_frame>Up to 30 days post-transplant or post-explant</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Powered Secondary Endpoint: GI bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Documented mucosal (GI tract and/or nasopharynx) bleeding, requiring blood transfusion (backed red blood cells) or hemoglobin drop (&gt;2 g/dL) without another identifiable source of bleeding AND meet one or more of the following:&#xD;
Identified mucosal bleeding by endoscope&#xD;
Appearance of overt melena, hematochezia, hematemesis, epistaxis&#xD;
Occult bleeding as evidenced by hemoccult-positive stool (2 consecutive testing to avoid false positive)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">399</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Evaheart LVAS (EVA2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class IV heart failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HeartMate 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class IV heart failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EVAHEART Left Ventricular Assist System (LVAS)</intervention_name>
    <description>Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.</description>
    <arm_group_label>Evaheart LVAS (EVA2)</arm_group_label>
    <other_name>EVA2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartMate 3</intervention_name>
    <description>Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.</description>
    <arm_group_label>HeartMate 3</arm_group_label>
    <other_name>HM3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The following is a list of general inclusion criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) ≤ 25%&#xD;
&#xD;
          -  NYHA Class IV heart failure&#xD;
&#xD;
          -  Patient is able to provide written informed consent&#xD;
&#xD;
          -  More detailed inclusion criteria information is noted in the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following is a list of general exclusion criteria:&#xD;
&#xD;
          -  Active, uncontrolled infection&#xD;
&#xD;
          -  Severe end organ dysfunction or failure&#xD;
&#xD;
          -  History of any organ transplant&#xD;
&#xD;
          -  Prosthetic mechanical aortic valve that will not be converted to a bioprosthesis&#xD;
&#xD;
          -  Patients with an unacceptable risk for successful LVAD implantation and maintenance&#xD;
&#xD;
          -  Patients refusing blood transfusion&#xD;
&#xD;
          -  Intolerant of anticoagulation therapy&#xD;
&#xD;
          -  Active psychiatric disorder, irreversible cognitive dysfunction or other psychosocial&#xD;
             behavior that impairs the ability of the patient to follow instructions, maintain&#xD;
             their device or their medical regimen&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current dependence on other mechanical circulatory support device at the time of&#xD;
             implant, other than IABP and Impella 5.0/5.5&#xD;
&#xD;
          -  Presence of condition other than heart failure that would limit survival to less than&#xD;
             24 months&#xD;
&#xD;
          -  More detailed exclusion criteria information is noted in the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tadashi Motomura, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Evaheart, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lizatte Martinez</last_name>
    <phone>713-520-7979</phone>
    <phone_ext>2</phone_ext>
    <email>lmartinez@evaheart-usa.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maricar Cruz</last_name>
    <phone>713-520-7979</phone>
    <phone_ext>1</phone_ext>
    <email>maricar@evaheart-usa.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UF Health Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janette &quot;Nicole&quot; Bostick</last_name>
      <phone>352-273-8938</phone>
      <email>Janette.Bostick@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Margiotti</last_name>
      <phone>317-338-6151</phone>
      <email>regina.margiotti@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Ashwin Ravichandran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Blanton, RN</last_name>
      <phone>502-587-4381</phone>
      <email>mary.blanton@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Slaughter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didjana Celkupa</last_name>
      <phone>617-636-8417</phone>
      <email>dcelkupa@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Michael Kiernan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Health Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Loffredo</last_name>
      <phone>717-531-6855</phone>
      <email>kloffredo@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Dowling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White, Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Negron, RN</last_name>
      <phone>214-820-9888</phone>
      <email>Francisco.Negron@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Dan Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Munoz-Beilis</last_name>
      <phone>713-798-8179</phone>
      <email>beilis@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Alexis Shafii, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Carreon, RN, CCRC</last_name>
      <phone>210-575-3064</phone>
      <email>Gloria.Carreon@MHShealth.com</email>
    </contact>
    <investigator>
      <last_name>Masahiro Ono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent Shively</last_name>
      <phone>206-598-3696</phone>
      <email>raackek@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Claudius Mahr, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lekha Nelavelli</last_name>
      <phone>608-262-9383</phone>
      <email>nelavelli@surgery.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>LVAS</keyword>
  <keyword>LVAD</keyword>
  <keyword>bridge-to-transplant</keyword>
  <keyword>rotary pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

